Loading...

China ophthalmology worth USD3.6 bn amid strong burst of growth

Image

 Articles

Rising diagnosis rates, government initiatives, social trends and diabetes are contributing to a strong burst of growth in the ophthalmology market in Asia. Rising numbers of affluent patients, national health insurance and the emerging middle classes are fuelling spending, including a USD3.6 bn market in China, where M&A in the sector is picking up rapidly. [Image: Embassy of PRC]

Read More

US delay in targeting Chinese patients

Image

29-Sep-16 Plans to turn an unused shoe factory in the US city of Auburn, Maine, into a medical tourism centre for Chinese patients are faltering. Chinese investment company Miracle Enterprise plans a 200-room recovery centre for wealthy Chinese seeking medical care at the Central Maine Medical Center. Miracle Enterprise needs to find USD40 mn, but is struggling to attract investors. [image: IMTJ]

Read More

China’s USD5 bn healthcare deal spree

Image

29-Sep-16 Chinese companies have announced more than USD5.2 bn of overseas healthcare acquisitions in 2016, a 15-fold jump from 2012. "Even though China’s pharmaceutical industry is still in the middle of consolidation and price wars, we hope to escape from this and do more work in terms of innovation and internationalization," said Shao Yan, CEO of China Grand Pharma. [image: China Grand Pharmaceutical and Healthcare Holdings Ltd]

Read More

Moves to fuse TCM with Western medicine gaining traction

Image

28-Sep-16 With the active ingredients in Traditional Chinese Medicine (TCM) now far better understood than ever before, a new range of hybrid TCM/Western treatments are wooing even the most cynical with their efficacy and lack of side-effects. Advances in research and development have enabled companies to integrate many of TCM's treatments and protocols with the latest technology and medical understanding. [image: HKTDC Research]

Read More

Merck’s Keytruda finds fast entry into China via medical tourism

Image

23-Sep-16 Merck’s immunotherapy cancer drug Keytruda is finding its way into China as the first imported drug approved for use under a pilot program on the resort island of Hainan intended to boost medical tourism. The zone in Boao is likely to attract patients who would otherwise travel to Hong Kong or Macau for drugs yet to be approved in China. [image: Anthony Wallace / AFP / Getty Images]

Read More